此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项评估 Fianlimab 和 Cemiplimab 组合与 Pembrolizumab 相比在完全切除的高危皮肤癌成人和青少年患者中的优越性的研究

2026年11月9日 更新者:Regeneron Pharmaceuticals

Fianlimab(抗 LAG-3)和 Cemiplimab 与 Pembrolizumab 在完全切除的高危黑色素瘤患者辅助环境中的 3 期试验

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with an approved medication called pembrolizumab.

The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to pembrolizumab in patients that have had melanoma removal surgery but are still at high risk for the recurrence of the disease. Pembrolizumab is an approved treatment in some countries in this clinical setting.

The study is looking at several other research questions, including:

  • What side effects may happen from receiving the study drugs.
  • How much study drug is in the blood at different times.
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects). Antibodies are proteins that are naturally found in the blood stream that fight infections.
  • How administering the study drugs might improve quality of life.

研究概览

研究类型

介入性

注册 (实际的)

1564

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Batumi、乔治亚州、6000
        • Cancer Center of Adjara
      • Tbilisi、乔治亚州、0159
        • JSC K. Eristavi National Center of Experimental and Clinical Surgery
      • Tbilisi、乔治亚州、0114
        • LTD New Hospitals
      • Tbilisi、乔治亚州、0112
        • Acad.Fridon Todua Medical Center- Research Institute of Clinical Medicine
      • Tbilisi、乔治亚州、0112
        • Israeli Georgian Medical Research Clinic Helsicore
      • Tbilisi、乔治亚州、0160
        • TIM - Tbilisi Institute of Medicine
    • Caucasus
      • Tbilisi、Caucasus、乔治亚州、0144
        • Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
      • Jerusalem、以色列、91120
        • Hadassah Medical Organization
      • Tel HaShomer、以色列、5265601
        • Sheba Medical Center
    • Northern District
      • Afula、Northern District、以色列、18340000
        • Haemek Medical Center
    • New Brunswick
      • Fredericton、New Brunswick、加拿大、E3B 5N5
        • Dr. Everett Chalmers Hospital
    • Ontario
      • Barrie、Ontario、加拿大、L4M 6M2
        • Royal Victoria Regional Health Centre
      • Toronto、Ontario、加拿大、M5G 2M9
        • Princess Margaret Cancer Centre
      • Toronto、Ontario、加拿大、M4N 3M5
        • Sunnybrook Health Sciences Centre
    • Gauteng
      • Johannesburg、Gauteng、南非、2196
        • The Medical Oncology Centre of Rosebank
      • Pretoria、Gauteng、南非、0081
        • Wilgers Oncology Centre
    • Western Cape
      • Cape Town、Western Cape、南非、7925
        • Groote Schuur Hospital
      • Kraaifontein、Western Cape、南非、7570
        • Cape Town Oncology Trials
      • Ankara、土耳其(türkiye)、06100
        • Ozel Liv Hospital
      • Ankara、土耳其(türkiye)、0906520
        • Memorial Ankara Hospital
      • Ankara、土耳其(türkiye)、06100
        • Sbu Doctor Abdurrahman Yurtaslan Ankara Onkoloji Suam
      • Ankara、土耳其(türkiye)、06010
        • Gulhane Research And Training Hospital
      • Edirne、土耳其(türkiye)、22030
        • Trakya University
      • Istanbul、土耳其(türkiye)、34450
        • Istanbul University Cerrahpasa at Cerrahpasa Medical Faculty
      • Istanbul、土耳其(türkiye)、81450
        • Istanbul Medeniyet University - Prof Dr Suleyman Yalcin Sehir Hospital
    • Adana
      • Yüreğir、Adana、土耳其(türkiye)、01230
        • Baskent University
    • Diyarbakır
      • Sur、Diyarbakır、土耳其(türkiye)、21200
        • Dicle University - Medical Faculty Campus
    • Kocaeli
      • İzmit、Kocaeli、土耳其(türkiye)、41380
        • Kocaeli University
    • Sehitkamil
      • Gaziantep、Sehitkamil、土耳其(türkiye)、27584
        • Gaziantep Medicalpoint Hospital
      • Veracruz、墨西哥、91910
        • Faicic Centro de Investigacion Clinica de Veracruz
    • Guanajuato
      • León、Guanajuato、墨西哥、37178
        • Preparaciones Oncologica SC
    • Jalisco
      • Guadalajara、Jalisco、墨西哥、44280
        • Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde
      • Guadalajara、Jalisco、墨西哥、44670
        • Pan American Clinical Research
    • Nuevo León
      • Monterrey、Nuevo León、墨西哥、64710
        • iCan Oncology
    • Sinaloa
      • Culiacán、Sinaloa、墨西哥、80020
        • Neurociencias Estudios Clinicos SC
    • Yucatán
      • Mérida、Yucatán、墨西哥、97134
        • Centro De Atencion E Investigacion Clinica En Oncologia SCP
      • Rio de Janeiro、巴西、23793-080
        • Instituto COI
      • São Paulo、巴西、01236030
        • Hemomed
      • São Paulo、巴西、04014-002
        • Sao Camilo Oncologia
      • São Paulo、巴西、01308-050
        • Hospital Sirio Libanes
    • Minas Gerais
      • Belo Horizonte、Minas Gerais、巴西、30130-090
        • Hospital das Clinicas da Universidade Federal de Minas Gerais
    • Paraná
      • Curitiba、Paraná、巴西、81520-060
        • Liga Paranaense de Combate ao Cancer - Hospital Erasto Gaertner
    • Rio Grande do Sul
      • Ijuí、Rio Grande do Sul、巴西、98700-000
        • Oncosite Centro De Pesquisa Em Oncologia
      • Passo Fundo、Rio Grande do Sul、巴西、99010-090
        • Instituto do Cancer em Hospital Sao Vicente de Paulo
      • Porto Alegre、Rio Grande do Sul、巴西、90035007
        • Hospital de Clinicas de Porto Alegre
      • Porto Alegre、Rio Grande do Sul、巴西、90619900
        • Centro de Pesquisa em Oncologia PUCRS
      • Porto Alegre、Rio Grande do Sul、巴西、90440140
        • Hospital Moinhos de vento
    • Rio de Janeiro
      • Santo Cristo、Rio de Janeiro、巴西、20220-410
        • INCA Instituto Nacional de Cancer
    • Santa Catarina
      • Itajaí、Santa Catarina、巴西、88301-220
        • Catarina Pesquisa Clinica
      • Joinville、Santa Catarina、巴西、89201260
        • Instituto Joinvilense de Hematologia e Oncologia
      • Lages、Santa Catarina、巴西、88501-001
        • Animi Unidade de Tratamento Oncologico
    • São Paulo
      • Barretos、São Paulo、巴西、14784400
        • Fundacao Pio XII - Hospital de Amor
      • Sorocaba、São Paulo、巴西、18052-210
        • Unimed Sorocaba
      • São José do Rio Preto、São Paulo、巴西、15090-000
        • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto - Hospital de Base
      • Thessaloniki、希腊、57001
        • Interbalkan Medical Center
      • Thessaloniki、希腊、54007
        • Ongology Theageneio Thessaloniki
      • Thessaloniki、希腊、54622
        • BioClinic Thessaloniki
    • Attica
      • Athens、Attica、希腊、11527
        • National and Kapodistrian University of Athens
      • Neo Faliro、Attica、希腊、18547
        • Metropolitan Hospital
      • Berlin、德国、10117
        • Charite Universitaetsmedizin Berlin
      • Bremen、德国、28325
        • Klinikum Bremen Ost
    • Baden-Wurttemberg
      • Mannheim、Baden-Wurttemberg、德国、68167
        • University Medical Center Mannheim
      • Tübingen、Baden-Wurttemberg、德国、72076
        • University of Tuebingen
    • Bavaria
      • Augsburg、Bavaria、德国、86179
        • University Hospital Augsburg
      • Erlangen、Bavaria、德国、91054
        • Dermatology Erlangen
      • Munich、Bavaria、德国、80337
        • LMU Klinikum
      • Regensburg、Bavaria、德国、93053
        • University Hospital of Regensburg
    • Hesse
      • Darmstadt、Hesse、德国、64283
        • Klinikum Darmstadt GmbH
      • Frankfurt am Main、Hesse、德国、60590
        • University Clinic Frankfurt
    • Lower Saxony
      • Göttingen、Lower Saxony、德国、37075
        • University Medical Center Goettingen
    • Mecklenburg-Vorpommern
      • Schwerin、Mecklenburg-Vorpommern、德国、19055
        • Helios Kliniken Schwerin
    • North Rhine-Westphalia
      • Bochum、North Rhine-Westphalia、德国、44791
        • Ruhr University Bochum
      • Essen、North Rhine-Westphalia、德国、45147
        • Universitatsklinikum Essen
      • Münster、North Rhine-Westphalia、德国、48157
        • Fachklinik Hornheide
      • Münster、North Rhine-Westphalia、德国、48149
        • University Hospital Muenster
    • Rhineland-Palatinate
      • Ludwigshafen am Rhein、Rhineland-Palatinate、德国、D-67063
        • Hautklinik
    • Saxony
      • Dresden、Saxony、德国、01307
        • University Hospital Dresden
    • Saxony-Anhalt
      • Quedlinburg、Saxony-Anhalt、德国、06484
        • Skin Cancer Center Harz
    • Schleswig-Holstein
      • Kiel、Schleswig-Holstein、德国、24105
        • University Hospital of Universitatsklinikum Schleswig Holstein (UKSH) Campus Kiel
      • Lübeck、Schleswig-Holstein、德国、23538
        • Universitatsklinikum Schleswig Holstein Campus Luebeck
    • Thuringia
      • Erfurt、Thuringia、德国、D-99089
        • Helios Klinikum Erfurt
      • Bari、意大利、70124
        • Istituto dei Tumori
      • Cuneo、意大利、12100
        • Azienda Ospedaliera Santa Croce i Carle
      • Milan、意大利、20141
        • Istituto Europeo di Oncologia
      • Naples、意大利、80131
        • Instituto Nazionale Tumori Fondazione Giovanni Pascale
      • Perugia、意大利、06132
        • University of Perugia
      • Rome、意大利、000168
        • Fondazione Policlinico Universitrio a. Gemelli - IRCCS
      • Rome、意大利、00128
        • Campus Bio-Medico di Roma
      • Rome、意大利、00167
        • Istituto Dermopatico dell'Immacolata
      • Trento、意大利、38122
        • Santa Chiara Hospital
      • Udine、意大利、33100
        • Azienda Sanitaria Universitaria del Friuli Centrale
    • An
      • Ancona、An、意大利、60020
        • Clinica Oncologica, AOU Riuniti Ancona
    • Campania
      • Naples、Campania、意大利、80121
        • U.O.C. Oncologia Medica ed Ematologia (U.O.C Medical Oncology and Hematology)
    • Forli Cesena
      • Meldola、Forli Cesena、意大利、47014
        • Istituto Romagnolo per lo Studio dei Tumori (IRST)
    • Lombardy
      • Milan、Lombardy、意大利、20089
        • Istituto Clinico Humanitas
      • Ostrava、捷克语、70852
        • University Hospital Ostrava
    • Brno Mesto
      • Brno、Brno Mesto、捷克语、65653
        • Masaryk Memorial Cancer Institute
    • North Central Czech Republic
      • Hradec Králové、North Central Czech Republic、捷克语、50005
        • University Hospital Hradec Kralove
    • Santiago Metropolitan
      • Santiago、Santiago Metropolitan、智利、7560907
        • Centro Oncologia de Precision Universidad Mayor
      • Santiago、Santiago Metropolitan、智利、7550000
        • Clinica UC San Carlos de Apoquindo
    • Valparaiso
      • Viña del Mar、Valparaiso、智利、2520598
        • Oncocentro APYS
      • Brussels、比利时、1200
        • Cliniques Universitaires Saint-Luc
    • Oost-Vlaanderen
      • Sint-Niklaas、Oost-Vlaanderen、比利时、9100
        • Vitaz campus Sint-Niklaas Moerland
    • West-Vlaanderen
      • Kortrijk、West-Vlaanderen、比利时、8500
        • AZ Groeninge
      • Avignon、法国、84918
        • Sainte Catherine Institut du Cancer Avignon Provence
      • Boulogne-Billancourt、法国、92100
        • N_Hôpital Ambroise-Paré
      • Clermont-Ferrand、法国、63003
        • CHU Estaing
      • Nice、法国、06202
        • Centre Hospitalier Universitaire De Nice Hopital De L Archet
      • Valence、法国、26000
        • Centre Hospitalier de Valence
      • Villejuif、法国、94805
        • Institut Gustave Roussy
    • Bourgogne-Franche-Comté
      • Dijon、Bourgogne-Franche-Comté、法国、21000
        • Centre Georges Francois Leclerc
    • Burgundy
      • Dijon、Burgundy、法国、21000
        • CHU-Dijon
    • Doubs
      • Besançon、Doubs、法国、25000
        • Besancon Regional University Hospital Center
    • Gironde
      • Bordeaux、Gironde、法国、33075
        • Chu De Bordeaux
    • Haute-Garonne
      • Toulouse、Haute-Garonne、法国、31059
        • Institut Claudius Regaud, IUCT-Oncopole
    • Hauts-de-France
      • Lille、Hauts-de-France、法国、59000
        • CHU de Lille
    • Herault
      • Montpellier、Herault、法国、34295
        • Service de Dermatologie CHU Saint Eloi
    • Isere
      • La Tronche、Isere、法国、38700
        • Centre Hospitalier Universitaire Grenoble Alpes
    • Normandy
      • Caen、Normandy、法国、14076
        • Centre Francois Baclesse (CFB)
    • Pays de la Loire Region
      • Le Mans、Pays de la Loire Region、法国、72037
        • Centre Hospitalier Le Mans
      • Nantes、Pays de la Loire Region、法国、44093
        • Nantes University Hospital
    • Picardie
      • Amiens、Picardie、法国、80000
        • CHU Amiens-Picardie
    • Île-de-France Region
      • Bobigny、Île-de-France Region、法国、93000
        • Hopital Avicenne
      • Créteil、Île-de-France Region、法国、94000
        • Hospital Henri Mondor
      • Paris、Île-de-France Region、法国、75010
        • Saint Louis Hospital
    • Mazxowieckie
      • Siedlce、Mazxowieckie、波兰、08-110
        • Mazowiecki Szpital Wojewodzki, Siedleckie Centrum Onkologii
    • Pomeranian Voivodeship
      • Gdansk、Pomeranian Voivodeship、波兰、80-214
        • UCK
      • Gdansk、Pomeranian Voivodeship、波兰、80-219
        • Copernicus Podmiot Leczniczy Sp. z o.o.Wojewodzie Centrum Onkologii
      • Słupsk、Pomeranian Voivodeship、波兰、76-200
        • Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Słupsku Sp. z o.o.
    • Wielkopolska
      • Poznan、Wielkopolska、波兰、60-788
        • Poznan University of Meidcla Science
    • New South Wales
      • Blacktown、New South Wales、澳大利亚、2148
        • Blacktown Cancer and Haematology Centre - Blacktown Hospital
      • Lismore、New South Wales、澳大利亚、2480
        • Lismore Base Hospital
      • Liverpool、New South Wales、澳大利亚、2170
        • Liverpool Hospital - Cancer Therapy Centre
      • Wollstonecraft、New South Wales、澳大利亚、2065
        • Melanoma Institute of Australia
    • South Australia
      • Bedford Park、South Australia、澳大利亚、5042
        • Flinders Medical Centre
      • North Adelaide、South Australia、澳大利亚、5006
        • Calvary North Adelaide Hospital
    • Victoria
      • Box Hill、Victoria、澳大利亚、3128
        • Eastern Health
      • Geelong、Victoria、澳大利亚、3220
        • Andrew Love Cancer Centre
      • Melbourne、Victoria、澳大利亚、3004
        • Alfred Hospital
    • Western Australia
      • Nedlands、Western Australia、澳大利亚、6009
        • One Clinical Research at Hollywood Private Hospital
      • Cork、爱尔兰、T12 EC8P
        • Cork University Hospital
      • Dublin、爱尔兰、D09 V2N0
        • Beaumont Hospital
      • Dublin、爱尔兰、DO4YN63
        • St Vincents University Hospital
    • Connacht
      • Galway、Connacht、爱尔兰、H91 YR71
        • Galway University Hospital
      • Iași、罗马尼亚、700106
        • Centrul De Oncologie Euroclinic
    • Bucharest
      • Bucharest、Bucharest、罗马尼亚、022328
        • Institute of Oncology Bucharest
    • Cluj
      • Cluj-Napoca、Cluj、罗马尼亚、400015
        • Cardiomed
      • Cluj-Napoca、Cluj、罗马尼亚、400015
        • Institute of Oncology Prof. Dr Ion Chirircuta
      • Floreşti、Cluj、罗马尼亚、407280
        • Radiotherapy Center Cluj
    • Dolj
      • Craiova、Dolj、罗马尼亚、200347
        • Sfantul Nectarie Oncology Center
    • Timiș County
      • Timișoara、Timiș County、罗马尼亚、300166
        • Oncocenter Oncologie Clinica S.R.L
      • Timișoara、Timiș County、罗马尼亚、300239
        • Oncomed
    • California
      • La Jolla、California、美国、92093
        • UC San Diego
      • San Francisco、California、美国、94158
        • UCSF Medical Center at Mission Bay
      • Santa Monica、California、美国、90404
        • John Wayne Cancer Institute (JWCI)
    • Colorado
      • Englewood、Colorado、美国、80113
        • The Melanoma And Skin Cancer Institute
    • Florida
      • Miami、Florida、美国、33176
        • Miami Cancer Institute at Baptist Health, Inc.
      • Orlando、Florida、美国、32806
        • Orlando Health
      • Tampa、Florida、美国、33612
        • Moffitt Cancer Center
    • Illinois
      • Chicago、Illinois、美国、60611
        • Northwestern University
    • Massachusetts
      • Boston、Massachusetts、美国、02215
        • Dana-Farber Cancer Institute
      • Boston、Massachusetts、美国、02114
        • Massachusetts General Hospital
    • Michigan
      • Detroit、Michigan、美国、48201
        • Karmanos Cancer Institute
    • New Jersey
      • New Brunswick、New Jersey、美国、08901
        • Rutgers Cancer Institute of New Jersey
    • New York
      • New York、New York、美国、10032
        • Columbia University
      • New York、New York、美国、10016
        • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
      • Rochester、New York、美国、14642
        • University of Rochester
    • North Carolina
      • Chapel Hill、North Carolina、美国、27599
        • Lineberger Comprehensive Cancer Center
      • Durham、North Carolina、美国、27710
        • Duke Cancer Institute, University Hospital
    • Ohio
      • Cleveland、Ohio、美国、44195
        • Cleveland Clinic Foundation
      • Cleveland、Ohio、美国、44106
        • University Hospitals Cleveland Medical Center
      • Columbus、Ohio、美国、43210
        • The Ohio State University James Comprehensive Cancer Center
    • Pennsylvania
      • Easton、Pennsylvania、美国、18045
        • St Lukes University Health Network
      • Pittsburgh、Pennsylvania、美国、15213
        • University Of Pittsburgh
    • Tennessee
      • Knoxville、Tennessee、美国、37920
        • University of Tennessee Medical Center
      • Nashville、Tennessee、美国、37203-1625
        • Tennessee Oncology - Centennial Clinic Location
      • Nashville、Tennessee、美国、37203
        • Verdi Oncology
    • Texas
      • Dallas、Texas、美国、75390
        • UT Southwestern Medical Center
    • Utah
      • Murray、Utah、美国、84107
        • Intermountain Medical Center
    • Virginia
      • Charlottesville、Virginia、美国、22903
        • University of Virginia Medical Center
      • London、英国、NW1 2PG
        • University College London Hospitals
      • London、英国、EC1A 7BE
        • Saint Bartholomew's Hospital
      • Manchester、英国、M20 4BX
        • The Christie
      • Taunton、英国、TA1 5DA
        • Taunton and Somerset NHS Foundation Trust
    • Devon
      • Exeter、Devon、英国、EX2 5DW
        • Royal Devon and Exeter Hospital NHS Trust
    • Lothian
      • Edinburgh、Lothian、英国、EH4 2XU
        • Edinburgh Cancer Centre
    • Somerset
      • Bristol、Somerset、英国、BS2 8ED
        • Bristol Haematology And Oncology Centre (BHOC) - Bristol Cancer Institute
    • Surrey
      • Sutton、Surrey、英国、SM2 5PT
        • The Royal Marsden NHS Foundation Trust
    • West Midlands
      • Coventry、West Midlands、英国、CV2 2DX
        • University Hospital Coventry and Warwickshire Nhs Trust
      • Barcelona、西班牙、08036
        • Hospital Clinic de Barcelona
      • Barcelona、西班牙、08908
        • Catalan Institute of Oncology (ICO) Hospitalet
      • Barcelona、西班牙、08035
        • Hospital Vall d'Hebron
      • Granada、西班牙、18014
        • Hospital Universitario Virgen de las Nieves
      • Lugo、西班牙、27003
        • Hospital Universitario Lucus Augusti
      • Madrid、西班牙、28041
        • Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM
      • Madrid、西班牙、28046
        • Hospital Universitario La Pa<
      • Madrid、西班牙、28050
        • Centro Integral Oncologico HM Clara Campal
      • Madrid、西班牙、28007
        • Hospital General Universitario Gregorio Maranon
      • Seville、西班牙、41009
        • Hospital Universitario Virgen Macarena
      • Valencia、西班牙、46010
        • Incliva - Instituto de Investigacion Sanitaria
      • Valencia、西班牙、46009
        • Instituto Valenciano de Oncologia
    • Barcelona
      • Badalona、Barcelona、西班牙、08916
        • H. Germans Trias i Pujol, ICO-Badalona
    • Cantabria
      • Santander、Cantabria、西班牙、39008
        • Hospital Universitario Marques de Valdecilla
    • Catalonia
      • Barcelona、Catalonia、西班牙、08028
        • Instituto Oncologico Dr Rosell Hospital Universitari Quiron Dexeus Location
    • Principality of Asturias
      • Oviedo、Principality of Asturias、西班牙、33011
        • Hospital Universitario Central De Asturias
      • Caba、阿根廷、1061
        • DIABAID - Instituto de Asistencia Integral en Diabetes
    • Buenos Aires
      • Caba、Buenos Aires、阿根廷、1125
        • Fundacion Centro de Investigaciones para la Transformacion (CENIT)
      • Pergamino、Buenos Aires、阿根廷、B2700CPM
        • Centro de Investigacion Pergamino
    • Río Negro Province
      • Viedma、Río Negro Province、阿根廷、8500
        • Clinica Viedma S.A.
    • Santa Fe Province
      • Rosario、Santa Fe Province、阿根廷、S2000KZE
        • Instituto de Oncologia de Rosario
    • Tucumán Province
      • San Miguel de Tucumán、Tucumán Province、阿根廷、4000
        • Centro Medico San Roque

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

12年 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  1. All patients must be either stage IIB, IIC, III, or stage IV per American Joint Committee on Cancer (AJCC) 8th edition and have histologically confirmed melanoma that is completely surgically resected in order to be eligible as defined by the protocol
  2. Complete surgical resection must be performed within 12 weeks prior to randomization, and enrollment may occur only after satisfactory wound healing from the surgery
  3. All patients must have disease-free status documented by a complete physical examination and imaging studies within 4 weeks prior to randomization, as described in the protocol

Key Exclusion Criteria:

  1. Uveal melanoma
  2. Any evidence of residual disease after surgery by imaging, pathology, or cytology.
  3. Ongoing or recent (within 2 years) evidence of clinically significant autoimmune disease that required treatment
  4. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C (HCV) infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection, as described in the protocol
  5. Another malignancy that is currently progressing or that required active treatment in the past 5 years, as described in the protocol
  6. Participants with a history of myocarditis
  7. Adolescent patients (≥12 to <18 years old) with body weight <40 kg

Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Fianlimab HD + Cemiplimab

Patients will be administered one combination dose of fianlimab high dose (HD) and cemiplimab

Fianlimab will be administered by intravenous (IV) infusion every (Q) 3 weeks

其他名称:
  • REGN3767

Cemiplimab will be administered by IV infusion Q 3 weeks

其他名称:
  • REGN2810
  • 利布塔约
实验性的:Fianlimab LD + Cemiplimab

Patients will be administered one combination dose of fianlimab low dose (LD) and cemiplimab

Fianlimab will be administered by intravenous (IV) infusion every (Q) 3 weeks

其他名称:
  • REGN3767

Cemiplimab will be administered by IV infusion Q 3 weeks

其他名称:
  • REGN2810
  • 利布塔约
有源比较器:Pembrolizumab

Patients will be administered one dose of pembrolizumab co-infused with saline/dextrose placebo

Pembrolizumab will be administered by IV infusion Q 3 weeks

其他名称:
  • 可瑞达
  • 兰博利珠单抗
  • MK-3475

Matching placebo co-infused with pembrolizumab IV, will be administered by IV infusion Q 3 weeks

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Relapse free survival (RSF)
大体时间:Up to 5 Years

Time from randomization to the first documented recurrence of disease at any site (excluding new primary melanomas) or death from any cause, whichever occurs first.

Up to 5 Years

次要结果测量

结果测量
措施说明
大体时间
根据 EORTC QLQ-C30,全球健康状况/生活质量恶化的时间
大体时间:长达 5 年
长达 5 年
根据 EORTC QLQ-C30 的身体机能恶化时间
大体时间:长达 5 年
长达 5 年
根据 EORTC QLQ-C30 角色功能恶化的时间
大体时间:长达 5 年
长达 5 年
Distant metastasis-free survival (DMFS)
大体时间:Up to 5 Years

Time between the date of randomization and the date of the first distant metastasis.

Up to 5 Years
Overall survival (OS)
大体时间:Up to 5 Years

Time from randomization to the date of death.

Up to 5 Years
Occurrence of treatment-emergent adverse events (TEAEs)
大体时间:Up to 5 Years

A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.

Up to 5 Years
Occurrence of immune-mediated EAEs (im-EAEs)
大体时间:Up to 5 Years

imAEs are a unique set of toxicities thought to be caused by unrestrained cellular immune responses.

Up to 5 Years
Occurrence of serious adverse events (SAEs)
大体时间:Up to 5 Years

An SAE is any untoward medical occurrence that at any dose:

  • Results in death - includes all deaths, even those that appear to be completely unrelated to study drug (eg, a car accident in which a patient is a passenger).
  • Is life-threatening
  • Requires in-patient hospitalization or prolongation of existing hospitalization.
  • Results in persistent or significant disability/incapacity
  • Is a congenital anomaly/birth defect.
  • Is an important medical event
Up to 5 Years
Occurrence of adverse events of special interest (AESIs)
大体时间:Up to 5 Years

An AESI (serious or non-serious) is one of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the sponsor can be appropriate. Such an event might warrant further investigation in order to characterize and understand it

Up to 5 Years
Occurrence of TEAEs resulting in death
大体时间:Up to 5 Years

A TEAE resulting in death is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.

Up to 5 Years
Occurrence of dose-limiting toxicity (DLT)
大体时间:Up to 5 Years

A DLT is defined as a study-drug related TEAE, including imAEs, that could preclude enrolling additional adolescent patients at the selected dose. Dose-limiting toxicity will be evaluated in adolescents only.

Up to 5 Years
Occurrence of interruption or discontinuation of study drug(s) due to TEAE
大体时间:Up to 5 Years

A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.

Up to 5 Years
Occurrence of laboratory abnormalities
大体时间:Up to 5 Years

As assessed by the NCI-CTCAE grading system (≥ Grade 3 or higher)

Up to 5 Years
Concentrations of fianlimab in serum over time
大体时间:Up to 5 Years

The concentrations of fianlimab over time will be summarized by descriptive statistics by study arm for the overall population and for adolescent patients.

Up to 5 Years
Concentrations of cemiplimab in serum over time
大体时间:Up to 5 Years

The concentrations of cemiplimab over time will be summarized by descriptive statistics by study arm for the overall population and for adolescent patients.

Up to 5 Years
Concentration of finalimab anti-drug antibodies (ADA) and neutralizing antibodies
大体时间:Up to 5 Years

Immunogenicity will be characterized per drug molecule by ADA and NAb status.

Up to 5 Years
Concentration of cemiplimab anti-drug antibodies (ADA) and neutralizing antibodies
大体时间:Up to 5 Years

Immunogenicity will be characterized per drug molecule by ADA and NAb status.

Up to 5 Years
Patient report outcomes (PRO) for adults as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
大体时间:Up to 5 Year

The EORTC QLQ-C30 (Version 3) uses for the questions 1 to 28 a 4-point scale. The scale scores from 1 to 4: 1 ("Not at all"), 2 ("A little"), 3 ("Quite a bit") and 4 ("Very much"). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome.

The EORTC QLQ-C30 (Version 3) uses for the questions 29 and 30 a 7-points scale. The scale scores from 1 to 7: 1 ("very poor") to 7 ("excellent"). Half points are not allowed. The range is 6. More points are considered to have a better outcome.

Up to 5 Year
PRO for adults as measured by the European Quality of Life Dimension 5 (EQ-5D-5L)
大体时间:Up to 5 Years

The EQ-5D-5L a descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

Up to 5 Years
PRO for adults as measured by the Functional Assessment of Cancer Therapy (FACT) - melanoma
大体时间:Up to 5 Years

The FACT-M is a melanoma-specific quality of life questionnaire that is composed of items from the Functional Assessment of Cancer Therapy-General (FACT-G). The FACT-M is scored on a 5 point Likert-scale: "Not at all", "A little bit", "Somewhat", "Quite a bit", and "Very much.". A Higher score represents higher Health Related Quality of Life (HRQoL).

Up to 5 Years
PRO for adults as determined by the Patient Global Impressions Scale (PGIS)
大体时间:Up to 5 Years

The PGIS is a single 1-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time by using a 4-point Likert scale that ranges from (1) = "none (no symptoms)" to (4) = "severe".

Up to 5 Years
PRO for adults as determined by the Patient Global Impressions of Change Scale (PGIC)
大体时间:Up to 5 Years

The PGIC is a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change since starting treatment as rated on a 5-point Likert scale anchored by (1) "much better" to (5) "much worse", with (4) = "no change".

Up to 5 Years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Clinical Trial Management、Regeneron Pharmaceuticals

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年1月16日

初级完成 (估计的)

2027年1月15日

研究完成 (估计的)

2030年4月3日

研究注册日期

首次提交

2022年10月14日

首先提交符合 QC 标准的

2022年10月31日

首次发布 (实际的)

2022年11月8日

研究记录更新

最后更新发布 (实际的)

2026年11月10日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

IPD 共享时间框架

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy.

IPD 共享访问标准

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 分析代码
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅